Science 37 is a disruptive innovation that was designed with the patient’s needs in mind, and is uniquely positioned to improve patient access to research by connecting patients securely and conveniently to researchers, regardless of where these patients.
Boston, MA (PRWEB) September 17, 2015
At The Conference Forum’s DPharm: Disruptive Innovations to Advance Clinical Trials U.S. conference last week, Science 37 was awarded the Disruptive Innovator of the Year award by a panel of judges made up of pharmaceutical industry experts, research scientists, and patient advocates.
“Science 37 was the most 'disruptive' to the current ways of doing things and had the best potential to increase patients’ involvement in clinical trials,” said patient advocate judge, Jamie Goldfarb.
The judging panel included:
- Lori Abrams, Bristol-Myers Squibb
- Jamie Goldfarb, Patient Advocate
- Andreas Koester, MD, PhD, Janssen
- Craig Lipset, MBA, Pfizer
- Paulo Moreira, EMD Serono
- Stephanie Petrone, Novartis Oncology
- Chandra Ramanathan, PhD, MBA, Bayer AG
- Katherine Vandebelt, Eli Lilly and Company
Sarah Krüg, CEO of CANCER101 and Executive Director of The Society for Participatory Medicine, and Chair of the Disruptive Innovator of the Year awards process, stated, “Science 37 is a disruptive innovation that was designed with the patient’s needs in mind, and is uniquely positioned to improve patient access to research by connecting patients securely and conveniently to researchers, regardless of where these patients live. This revolutionary technology will help address the unmet needs of various patient populations, especially those with rare diseases and the underserved."
Science 37 Co-founder and CEO Noah Craft, MD PhD stated, “The clinical trial process is ripe for disruption, and we are honored to be recognized for our commitment to innovate both technology and processes for better, faster, people-powered science. We believe that Science 37’s proprietary technology, operating model, and trials management process will unlock access to expert researchers for patients who can benefit from participating in trials, and unlock access to patients for those researchers who struggle to find enough participants for research. The convergence of my previous experiences in clinical research, telemedicine and healthcare technology informed how we built our new platform to accelerate drug development. We are excited to harvest the power of emerging technologies and strategic partnerships to bring safe and effective cures more quickly to patients who are waiting. This recognition from our industry peers is inspiring for our whole team.”
About Science 37
Science 37 safely and securely connects people to the best clinical research in the world through “end-to-end” clinical trials services. We unlock access so researchers can find the right patients, and patients can find the right trials. Our patient-centric mobile research platform, NORA, helps people anywhere participate in research. Working with Science 37 makes clinical research faster, accelerates biomedical discovery, and reduces clinical trial costs. Science 37 enables better, faster people-powered science. Learn more: http://science37.com
DPharm is the definitive event for innovators in the clinical trial space. The entire conference introduces novel and bold approaches to help attendees think differently about how to do clinical trials for the benefit of patients. DPharm launched five years ago and is held annually each September in Boston and the conference also has a European program in London in February. DPharm is organized by the Conference Forum. The Conference Forum develops specialized events both public and private as well as research groups and advisory boards for professionals in the life science industry. See more at: http://theconferenceforum.org